Validation study of new febrile neutropenia guideline-Comparative study between oral levofloxacin and parenteral cefepime in low-risk patients with febrile neutropenia

Validation study of new febrile neutropenia guideline-Comparative study between oral levofloxacin and parenteral cefepime in low-risk patients with febrile neutropenia - Treatment for FN in Low-Risk patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000396

Enrollment

200

Registered

2006-04-04

Start date

2005-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Febrile neutropenia

Interventions

CFPM 4g,1h-div, q12 LVFX 200mg, tid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Solid tumor, multiple myeloma, acute leukemia Axiillary temperature greater than 38C on one occasion or greater than 37.5C lasting for more than 1 hour Absolute neutrophil count of less than 500/microL Low-risk patient

Exclusion criteria

Exclusion criteria: Poor-risk acute leukemia patients Isolation of microorganism resistant to the study drugs Past history of allergy to beta-lactum or study drugs Pregnant or lactating woman Age of 15 years or younger Antimicrobial treatment within 3 months prior to the study entry Allegenic hematopoietic stem cell transplantation

Design outcomes

Primary

Measure	Time frame
Treatment efficacy at 7 days after antimicrobiral therapy	—

Secondary

Measure	Time frame
Adverse events, treatment results in 3-5 days after the start of therapy, succes rate as an outpatient, survival, antibacterial effect	—

Countries

Japan

Contacts

Public ContactKazuo Tamura

Fukuoka University Depatment of Internal Medicine

ktamura@fukuoka-u.ac.jp092-801-1011

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026